Table 2.
List of few vaccine candidates against COVID-19 currently in Phase I-III trials.
| Name of the candidate | Sponsor | Institute | Funding agency | Trial phase |
|---|---|---|---|---|
| Bacillus Calmette-Guerin (BCG) live-attenuated vaccine | University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital | University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital | Murdoch Children’s Research Institute; UMC Utrecht | II/III |
| INO-4800 (DNA vaccine, plasmid) | Inovio Pharmaceuticals; Advaccine | University of Pennsylvania, Center for Pharmaceutical Research, Kansas City. Mo. & the Korea National Institute of Health (KNIH) | Inovio Pharmaceuticals, CEPI & the International Vaccine Institute (IVI) | II/III |
| ARCoV (mRNA-based vaccine) | Walvax Biotechnology Co., ltd.; Abogen Biosciences Co. ltd.; Yuxi Walvax Biotechnology Co., ltd. | Xiangfen CDC | Walvax Biotechnology Co., ltd.; Abogen Biosciences Co. ltd.; Yuxi Walvax Biotechnology Co., ltd. | III |
| Vidprevtyn (Recombinant protein vaccine) | Sanofi; GlaxoSmithKline | Various | OWS and the U.S. Department of Defense | III |
| Unnamed vaccine candidate (Recombinant vaccine, Sf9 cells) | WestVac Biopharma Co., ltd.; West China Hospital; Sichuan University; | Jiangsu Province Centers for Disease Control and Prevention | WestVac Biopharma Co., ltd.; West China Hospital; Sichuan University; | III |
| GBP510 (Nanoparticle vaccine) | SK bioscience Co., ltd.; GSK; University of Washington; CEPI | Multiple | SK bioscience Co., ltd.; GSK; University of Washington; CEPI | III |
| CVnCoV (mRNA-based vaccine) | CureVac; GSK | CureVac (Various study sites in Europe) |
The German federal government | IIb/III |
| V-01 (Recombinant protein vaccine) | Guangdong Provincial Center for Disease Control and Prevention; Gaozhou Municipal Center for Disease Control and Prevention; Zhuhai Livzonumab Biotechnology Co., ltd. | Livzon Mabpharm Inc. | Zhuhai Livzonumab Biotechnology Co. | III |
| COVI-VAC (Intranasal vaccine) | Codagenix; Serum Institute of India | Codagenix; Serum Institute of India | Codagenix; Serum Institute of India | I |
| BBV154 (Intranasal vaccine) | Bharat Biotech | Various | Bharat Biotech | II/III |
| BNT162 (mRNA-based vaccine) | Pfizer, BioNTech | Multiple study sites in Europe, North America, and China | Pfizer, BioNTech | I/ II/III |
| Nanocovax (Recombinant vaccine, Spike protein) | Nanogen Biopharmaceuticals | Military Medical Academy (Vietnam) | Nanogen Biopharmaceutical | III |
| Razi Cov Pars (Recombinant vaccine, Spike protein) | Razi Vaccine and Serum Research Institute | Tehran Rasoul Akram Hospital; Karaj, Hesarak, Razi Vaccine and Serum Research Institute | Razi Vaccine and Serum Research Institute | III |
| S-268019 (Recombinant protein vaccine) | Shionogi & Co., ltd; Japan Agency for Medical Research and Development | – | Shionogi & Co., ltd; Japan Agency for Medical Research and Development | II/III |
| Unnamed vaccine candidate (Recombinant vaccine, Sf9 cells) | WestVac Biopharma Co., ltd.; West China Hospital; Sichuan University; | Jiangsu Province Centers for Disease Control and Prevention | WestVac Biopharma Co., ltd. | III |
| GBP510 (Nanoparticle vaccine) | SK bioscience Co., ltd.; GSK; University of Washington; CEPI | Various | GSK; CEPI | III |
| SCB-2019 (Protein subunit vaccine) | GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax; CEPI | Linear Clinical Research (Australia) | GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax; CEPI | III |
Source: Regulatory Affairs Professional Society. Craven J, Vaccine Tracker. https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker47.